The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.It ...

A new generative AI model rapidly generates diverse antimicrobial peptide structures for screening against ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Can-Fite’s lead drug candidate, Piclidenoson ... who will share insight into the Company’s current development pipeline and upcoming milestones. Strategically positioned with multiple out ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

GSK said this reflected progress in late stage drug development, including several ... They’ve been held back by concern over the pipeline and what is seen as few near-term catalysts, down ...

It added that it expects further growth to be boosted by its strong pipeline of new drugs, with 71 specialty medicines and vaccines now in clinical development. As a result, the company said it is ...